Table 2.
Primary and secondary outcomes according to the development of AKI at the latest follow-up*
| AKI (n = 72) | No AKI (n = 24) | Effect estimate (95% CI) | p value | |
|---|---|---|---|---|
| Primary outcome | ||||
| Hospital mortality | 28 (38.9) | 4 (16.7) | 1.32 (0.48−3.63)a | 0.597 |
| Secondary outcomes | ||||
| ICU mortality | 26 (36.1) | 3 (12.5) | 1.26 (0.40−4.00)a | 0.690 |
| Duration of ventilation, days | 15.1 (9.8−24.0) | 12.6 (9.1−16.6) | 0.46 (0.22−0.97)b | 0.041 |
| In survivors | 16.6 (10.6−27.5) | 13.1 (10.1−16.1) | ||
| ICU length of stay, days | 16.0 (10.0−24.2) | 13.5 (10.0−17.2) | 0.46 (0.22−0.97)b | 0.041 |
| In survivors | 17.0 (11.5−27.5) | 14.0 (11.0−17.0) | ||
| Hospital length of stay | 27.5 (16.8−35.0) | 25.0 (19.8−31.2) | 0.36 (0.12−1.04)b | 0.058 |
| In survivors | 32.0 (27.0−38.2) | 25.0 (20.0−32.0) |
Data are median (quartile 25–75%) or n (%). Percentages may not total 100 because of rounding. ICU, intensive care unit; CI, confidence interval; AKI, acute kidney injury.
*
Latest follow-up at April 20, 2020.
a
Effect estimate is hazard ratio from a Cox proportional hazard model with inverse probability of treatment weighting.
b
Effect estimate is sub-distribution hazard ratio from an unadjusted Fine-Gray competing risk model with death before the event as the competing risk and with inverse probability of treatment weighting.